Robocath, based in Rouen, develops a robotics device called R-one for treating cardiovascular disease that protects physicians from exposure to X-rays while still interacting with the patient.
R-one, which is protected by 20 patents, is still in approval stages and is currently seeking its CE mark. It will be released in Europe and the Middle East initially in 2018. The company anticipates that the market for the device will eventually be worth €4.5 billion.
“R-one is currently the only robotic assistance platform for interventional cardiology developed in Europe,” said Philippe Bencteux, chairman of Robocath. “We plan to build on this technological edge to enter the European market next year. Given our many strengths, we will also continue to design sophisticated robotics solutions, helping to usher in a new era of medicine to benefit physicians and patients.”